Company intelligence / Profile preview

Apaxen

Gosselies/, Wallonia Region, Belgiumapaxen.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Apaxen’s lead program, MFC‑1040, has demonstrated significant efficacy in preclinical rodent models for pulmonary hypertension by targeting the inflammatory cascade via inhibition of MIF and its receptor CD74. The company aims to advance this candidate into clinical proof-of-concept studies for PAH and explore additional indications involving chronic inflammation.

Therapeutic areas: PulmonologyCardiovascularNeurology
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

MFC-1040

Pre-clinical

Indications: Pulmonary arterial hypertension, Idiopathic pulmonary fibrosis

Partnerships

Theodorus Fund/Be Angels syndicate as investors/supporters rather than operational partners

Beyond the preview

Go deeper on Apaxen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apaxen.

Explore the full profile